Researchers is demonstrably improved this development of an novel therapy for cardiac amyloidosis, utilizing Attruby. Early trial results suggests potential benefits for those suffering by this serious illness. This emphasis underscores BridgeBio's dedication to managing unmet healthcare needs in the cardiology space. Attruby: BridgeBio's Novel Ap